ExpreS2ion Biotech (EXPRS2) H C Andersen Capital Life Science Seminar summary

Company overview and technology platform

• Operates a protein expression platform (ExpreS2) with a vaccine pipeline and services/CRO business, employing about 20 FTEs.

• Owns 34% of AdaptVac, leveraging virus-like particle technology, and listed on Nasdaq First North Growth Market since 2016.

• ExpreS2 platform validated in phase III clinical trials, including a COVID-19 vaccine developed by Bavarian Nordic that met its primary endpoint in 2023.

• Multiple clinical trials in malaria vaccines use ExpreS2 technology, with ongoing collaborations with University of Oxford.

Management and advisory

• Leadership and advisory team has over 200 years of combined experience in drug development, finance, and research.

• Oncology Scientific Advisory Board includes leading global experts in breast cancer and oncology.

Vaccine pipeline and scientific progress

• Pipeline includes ES2B-C001 (HER2+ breast cancer, late preclinical), ES2B-1002 (cytomegalovirus, lead optimization), and early-stage influenza and Nipah virus vaccine projects, with an undisclosed exploratory project.

• ES2B-C001 targets all four HER2 epitopes, aiming to overcome resistance seen with current monoclonal antibody therapies, and shows strong in vitro and in vivo efficacy, including in trastuzumab-resistant cells.

• CMV vaccine project developed in partnership with Evaxion Biotech, utilizing AI-designed antigens and ExpreS2ion's protein production.

• Early-stage influenza and Nipah virus vaccine projects are largely financed by non-dilutive funding.